TCR Compositions Optimizing Antigen Reactivity and Reducing Cross-Reactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current engineered T-cell therapies for cancer treatment face challenges in achieving specific targeting of cancer antigens while minimizing cross-reactivity with healthy cells, leading to severe side effects and regulatory approval issues due to the complexity and heterogeneity of cancer cells.
Innovation Solution
The development of T cell receptor (TCR) compositions and methods that optimize T-cells for reactivity to specific peptides with reduced cross-reactivity to non-target peptides, involving culturing conditions that enhance T-cell activation and validation, including differentiation of dendritic cells and co-culturing with CD8+ T-cells, followed by sequencing and validation of TCRs for targeted cancer peptides like NY-ESO-1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the affinity of TCRs in engineered T-cells is increased to cancer antigens, then the efficacy of cancer treatment is improved, but the affinity to non-cancer-specific peptides increases, resulting in severe and intolerable side effects
Solution Approach 1:
The patent applies local quality by engineering specific regions of the TCR (particularly the CDR3 loops) to have high affinity for cancer antigens while maintaining lower affinity for non-cancer peptides. This is achieved through directed evolution and selection processes that optimize local amino acid sequences in the TCR binding interface, allowing differential recognition between target and non-target antigens.
Solution Approach 2:
The patent employs parameter changes by systematically modifying TCR affinity parameters through iterative selection and engineering. The process involves changing binding kinetics parameters (on-rate, off-rate) and specificity parameters by introducing mutations and selecting for optimal binding characteristics that maximize cancer antigen recognition while minimizing cross-reactivity.
2Ease of manufacture
If conventional TCR engineering methods are used, then T-cells can be generated, but they show efficacious results only in vitro and rarely duplicate results in vivo
Solution Approach 1:
The patent applies preliminary action by performing extensive TCR optimization and validation in vitro before in vivo application. The method includes pre-selecting TCRs with optimal binding characteristics, validating their specificity against panels of peptides, and engineering them to have enhanced stability and function. This preliminary optimization ensures that only TCRs with proven efficacy and specificity proceed to in vivo testing, improving the likelihood of successful translation.
Solution Approach 2:
The patent employs feedback mechanisms by using in vitro validation results to guide further TCR engineering iterations. The process involves testing TCR candidates against cancer antigens and non-cancer peptides, analyzing binding characteristics and cellular responses, and using this feedback information to refine and optimize subsequent TCR designs, creating a continuous improvement loop that enhances in vivo performance.
3Measurement precision
If T-cells are engineered with high affinity TCRs, then cancer target recognition is enhanced, but dangerous cross-reactivity occurs that halts development of therapeutic products
Solution Approach 1:
The patent applies partial action by engineering TCRs with moderate to high affinity for cancer antigens rather than extremely high affinity, and by using combinatorial approaches where multiple TCRs with different specificities are used together. This partial optimization approach balances target recognition with safety, avoiding the extreme affinity that would cause dangerous cross-reactivity while maintaining sufficient efficacy.
Solution Approach 2:
The patent employs preliminary anti-action by proactively testing and selecting against TCRs that show cross-reactivity to non-cancer peptides before they are used in therapy. The method includes comprehensive screening against panels of self-peptides and non-target antigens, and using negative selection to eliminate candidates with dangerous cross-reactivity profiles, thereby preventing harmful effects before they occur.
Data Source
AI summary
Provided are methods for isolating T-cells with T cell receptors (TCRs) optimized for reactivity to specific peptides and decreased cross-reactivity to non-target peptides. Advantageously, TCRs of the invention can be optimized to target cancer antigens and peptides while having reducing reactivity to healthy cells. Methods of the invention utilize a novel combination of culturing conditions that increase T-cell activation and allow for validation of TCR activity. Culturing conditions of the invention further reduce culturing times generally needed to achieve expanded reactive T-cells. Because of the robust nature of the activation and validation conditions of the present invention, variants of identified TCRs can also be optimized and validated for their response to peptides, including cancer peptides.